Gregory J. Tsongalis, BS, MS, PhD
Title(s):
Professor of Pathology and Laboratory Medicine
Additional Titles/Positions/Affiliations:
Director, Clinical Genomics and Advanced Technology (CGAT)
Department(s):
Pathology and Laboratory Medicine
Education:
Univ. of Massachusetts, Amherst, BS, 1984
Quinnipiac College, MHS, 1986
Univ. of Medicine and Dentistry of New Jersey, PhD 1990
Uniiv. of North Carolina, Chapel Hill, post-doctoral 1990-1994
Programs:
Norris Cotton Cancer Center
Program in Experimental and Molecular Medicine
Websites:
DHMC-CGAT.com
Contact Information:
Department of Pathology and Laboratory Medicine
Dartmouth-Hitchcock Medical Center
One Medical Center Drive
Lebanon NH 03756
Office: WTRB 4th floor
Phone: 603-650-5498
Fax: 603-650-6120
Email: Gregory.J.Tsongalis@hitchcock.org
Assistant: Amber Erskine
Asst. Phone: 603-650-6821
Asst. Email: amber.j.erskine@hitchcock.org
Professional Interests:
Development of advanced diagnostic technologies and disease biomarker discovery.
Grant Information:
01/2014-12/30/15; Molecular profiling of tumor and ctDNA, riends of NCCC Scholar $50,000
03/01/13-01/31/2018; 1P20GM104416, Investigator / 2% COBRE Center for Molecular Epidemiology, Federal Direct Costs: $1,793,732
Selected Publications: |
|
A case of molecularly confirmed BAP1 Inactivated Melanocytic Tumor with retention of immunohistochemical expression: A confounding factor. MicroRNAs in graft-versus-host disease: a review of the latest data. BRAF V600E mutations are not an oncogenic driver of solitary xanthogranuloma and reticulohistiocytoma: Testing may be useful in screening for Erdheim-Chester disease. Third-Generation Sequencing in the Clinical Laboratory: Exploring the Advantages and Challenges of Nanopore Sequencing. How close are miRNAs from clinical practice? A perspective on the diagnostic and therapeutic market. Screening for Human Papillomavirus in a Low- and Middle-Income Country. Pancreatic cyst fluid harboring a KRAS mutation. Design of peptide nucleic acid probes on plasmonic gold nanorods for detection of circulating tumor DNA point mutations. Significant Expansion of Real-Time PCR Multiplexing with Traditional Chemistries using Amplitude Modulation. Ductal Carcinoma in Situ Biomarkers in a Precision Medicine Era: Current and Future Molecular-Based Testing. |
|
